Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience
-
Published:2020-06-07
Issue:11
Volume:99
Page:2565-2576
-
ISSN:0939-5555
-
Container-title:Annals of Hematology
-
language:en
-
Short-container-title:Ann Hematol
Author:
Bekoz Huseyin, Ozbalak Murat, Karadurmus Nuri, Paydas Semra, Turker Alev, Toptas Tayfur, Tuglular Tülin Firatli, Altuntas Fevzi, Cakar Merih Kizil, Sonmez Mehmet, Gulbas Zafer, Demir Nazlı, Kaynar Leylagul, Yildirim Rahsan, Karadogan Ihsan, Arat Mutlu, Kapucu Irem, Aslan Nevin Alayvaz, Ozkocaman Vildan, Turgut Mehmet, Yuksel Meltem Kurt, Ozcan Muhit, Hacioglu Sibel Kabukcu, Barista Ibrahim, Demirkaya Metin, Saydam Guray, Toprak Selami K., Yilmaz Mehmet, Demirkol Onur, Ferhanoglu BurhanORCID
Publisher
Springer Science and Business Media LLC
Subject
Hematology,General Medicine
Reference19 articles.
1. Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, Green MR, Gottlieb A, Peterson BA (1992) Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327(21):1478–1484. https://doi.org/10.1056/NEJM199211193272102 2. Viviani S, Zinzani PL, Rambaldi A, Brusamolino E, Levis A, Bonfante V, Vitolo U, Pulsoni A, Liberati AM, Specchia G, Valagussa P, Rossi A, Zaja F, Pogliani EM, Pregno P, Gotti M, Gallamini A, Rota Scalabrini D, Bonadonna G, Gianni AM, Michelangelo F, Gruppo Italiano di Terapie Innovative nei L, Intergruppo Italiano L (2011) ABVD versus BEACOPP for Hodgkin’s lymphoma when high-dose salvage is planned. N Engl J Med 365(3):203–212. https://doi.org/10.1056/NEJMoa1100340 3. Borchmann P, Haverkamp H, Lohri A, Mey U, Kreissl S, Greil R, Markova J, Feuring-Buske M, Meissner J, Duhrsen U, Ostermann H, Keller U, Maschmeyer G, Kuhnert G, Dietlein M, Kobe C, Eich H, Baues C, Stein H, Fuchs M, Diehl V, Engert A (2017) Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin’s lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group. The Lancet Oncology 18(4):454–463. https://doi.org/10.1016/S1470-2045(17)30103-1 4. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, Rodig SJ, Chapuy B, Ligon AH, Zhu L, Grosso JF, Kim SY, Timmerman JM, Shipp MA, Armand P (2015) PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med 372(4):311–319. https://doi.org/10.1056/NEJMoa1411087 5. Armand P, Shipp MA, Ribrag V, Michot JM, Zinzani PL, Kuruvilla J, Snyder ES, Ricart AD, Balakumaran A, Rose S, Moskowitz CH (2016) Programmed Death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. https://doi.org/10.1200/JCO.2016.67.3467
Cited by
19 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|